Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Inhibikase Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +31 vs. Q4 2025
- Shares held
- 115.1M
- +13.3M (+13.0%) vs. Q4 2025
- Total value
- $193.4M
- −$15.4M (−7.4%) vs. Q4 2025
- New holders
- 39
- 38 more added
- Sold out
- 8
- 14 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Trails Edge Capital Partners, LP | 8,057,345 | $13.5M | 3.19% | +1,879,221+30.4% | Added |
| Fairmount Funds Management LLC | 8,625,000 | $14.5M | 1.05% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 10,875,000 | $18.3M | 0.74% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 13,018,965 | $21.9M | 5.19% | 00.0% | Unchanged |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −1,376,395−100.0% | Sold out |
| Exome Asset Management LLC | 0 | $0 | 0.00% | −600,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −116,003−100.0% | Sold out |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −93,430−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −15,977−100.0% | Sold out |
| Sanctuary Advisors, LLC | 0 | $0 | 0.00% | −12,539−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −10,570−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −1,900−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |